Semen RNA-Based Biomarkers for Prostate Cancer Detection and Risk Stratification: A Prospective Multicenter Validation Study

Résumé fourni par la source

PURPOSE: We assessed the diagnostic performance of semen RNA-based biomarkers for detecting prostate cancer and differentiating cancer grade groups. MATERIALS AND METHODS: In a multicenter prospective study, semen samples were collected from men before undergoing prostate biopsy. RNA was extracted and sequenced to generate exome-wide gene expression profiles. Differentially expressed genes were selected and used to train a machine-learning classifier designed to detect prostate cancer with ≥ 95% sensitivity. The finalized model was locked and independently evaluated in a validation cohort. Histopathological diagnosis served as the reference standard. Model performance was further analyzed in relation to International Society of Urological Pathology Grade Group classification. RESULTS: Of 301 enrolled participants, 279 samples met quality criteria and were included in model development (training set: n = 199; validation set: n = 80). The median age and PSA level were 62 years and 5.70 ng/mL, respectively. In the validation cohort, the classifier achieved an AUC of 0.90, sensitivity of 92%, and specificity of 69%, with no significant performance difference compared with the training cohort. Importantly, high-risk cancers (International Society of Urological Pathology Grade Group ≥3) were ruled out with a negative predictive value of 96% in validation. CONCLUSIONS: This study demonstrates that noninvasive, high-accuracy prostate cancer tests can be developed using semen samples collected at home. The proposed test could potentially eliminate 60% to 70% of unnecessary biopsies, representing a substantial improvement in prostate cancer testing and risk stratification.

Ce résumé expose les affirmations des auteurs. BNTIC ne l’interprète pas comme une validation indépendante des résultats.